Search

Your search keyword '"N Di Muzio"' showing total 407 results
Start Over Author "N Di Muzio"
407 results on '"N Di Muzio"'

1. Cure without toxicity: development of a novel model predicting trifecta outcomes after salvage radiation therapy for recurrent prostate cancer after radical prostatectomy

Author

N. Fossati, R.J. Karnes, S.A. Boorjan, G. Motterle, A. Bossi, T. Kumar, N. Di Muzio, C. Cozzarini, B.Noris Chiorda, E. Mazzone, C.A. Bravi, A. Stabile, G. Gandaglia, V. Cucchiara, D. Bartkowiak, S. Shariat, G. Goldner, G. Devos, S. Joniau, C. Berghen, G. De Meerleer, H. Van Poppel, F. Montorsi, T. Wiegel, and A. Briganti

Subjects
Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2020
Full Text
View/download PDF

2. Changing patterns and predictors of salvage radiation therapy use over time in patients treated for post-prostatectomy biochemical recurrence: a trend analysis over a 20-year period from a multi institutional series

Author

G. Rosiello, N. Fossati, R.J. Karnes, S.A. Boorjan, G. Motterle, A. Bossi, T. Kumar, N. Di Muzio, C. Cozzarini, B.Noris Chiorda, M. Bandini, E. Mazzone, G. Gandaglia, P.I. Karakiewicz, D. Bartkowiak, S. Shariat, G. Goldner, G. Devos, S. Joniau, C. Berghen, G. De Meerleer, H. Van Poppel, F. Montorsi, T. Wiegel, and A. Briganti

Subjects
Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2020
Full Text
View/download PDF

3. Association between the extent of lymph node dissection and severe toxicity in men with prostate cancer treated with post-prostatectomy radiation therapy: results from a large multi-institutional series

Author

N. Fossati, R.J. Karnes, S. Boorjian, G. Motterle, A. Bossi, E. Mazzone, V. Cucchiara, S. Scuderi, E. Zito, G. Gandaglia, T. Kumar, N. Di Muzio, C. Cozzarini, B.Noris Chiorda, D. Bartkowiak, S. Shariat, G. Goldner, G. Devos, S. Joniau, C. Berghen, G. De Meerleer, H. Van Poppel, F. Montorsi, T. Wiegel, and A. Briganti

Subjects
Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2020
Full Text
View/download PDF

4. Assessing the impact of salvage radiation therapy field after radical prostatectomy: a long-term analysis from a large multi-institutional series

Author

D. Robesti, N. Fossati, R.J. Karnes, S.A. Boorjan, G. Motterle, A. Bossi, T. Kumar, N. Di Muzio, C. Cozzarini, B.Noris Chiorda, E. Mazzone, G. Giorgio, B. Francesco, S. Simone, D. Bartkowiak, G. Goldner, S. Shariat, G. Devos, S. Joniau, C. Berghen, G. De Meerleer, H. Van Poppel, F. Montorsi, T. Wiegel, and A. Briganti

Subjects
Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2020
Full Text
View/download PDF

5. Assessing the optimal timing of salvage radiation therapy administration after radical prostatectomy: a stage-specific analysis from a large multi-institutional series

Author

D. Robesti, N. Fossati, J.R. Karnes, S.A. Boorjan, G. Motterle, A. Bossi, T. Kumar, N. Di Muzio, C. Cozzarini, B.Noris Chiorda, E. Mazzone, F. Barletta, A. Rizzo, D. Cannoletta, G. Gandaglia, D. Bartkowiak, S. Shariat, G. Goldner, G. Devos, S. Joniau, C. Berghen, G. De Meerleer, H. Van Poppel, F. Montorsi, T. Wiegel, and A. Briganti

Subjects
Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2020
Full Text
View/download PDF

6. Assessing the impact of salvage radiation therapy field after radical prostatectomy: A long-term analysis from a large multi-institutional series

Author

N. Fossati, R.J. Karnes, S.A. Boorjian, G. Motterle, A. Bossi, T. Kumar, N. Di Muzio, C. Cozzarini, B. Noris Chiorda, E. Mazzone, G. Gandaglia, F. Barletta, S. Scuderi, D. Robesti, D. Bartkowiak, S. Shariat, G. Goldner, G. Devos, S. Joniau, C. Berghen, G. De Meerleer, H. Van Poppel, F. Montorsi, T. Wiegel, and A. Briganti

Subjects
Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2020
Full Text
View/download PDF

7. Assessing the optimal timing of salvage radiation therapy administration after radical prostatectomy: A stage-specific analysis from a large multi-institutional series

Author

N. Fossati, R.J. Karnes, S.A. Boorjian, G. Motterle, A. Bossi, T. Kumar, N. Di Muzio, C. Cozzarini, B. Noris Chiorda, E. Mazzone, G. Gandaglia, F. Barletta, A. Rizzo, D. Cannoletta, D. Bartkowiak, S. Shariat, G. Goldner, G. Devos, S. Joniau, C. Berghen, G. De Meerleer, H. Van Poppel, F. Montorsi, T. Wiegel, and A. Briganti

Subjects
Diseases of the genitourinary system. Urology, RC870-923, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2020
Full Text
View/download PDF

8. PD-0415 Pelvic RT in prostate cancer: late intestinal toxicity is modulated by severity of acute symptoms

Author

A. Gebbia, F. Munoz, A. Magli, D. Cante, E. Garibaldi, B. Noris Chiorda, G. Girelli, E. Villa, A. Faiella, J.M. Waskiewicz, B. Avuzzi, A. Pastorino, E. Moretti, L. Rago, A. Bresolin, C. Bianconi, F. Badenchini, T. Rancati, R. Valdagni, V. Vavassori, M. Gatti, G. Sanguineti, N. Di Muzio, C. Fiorino, and C. Cozzarini

Subjects
Oncology, Radiology, Nuclear Medicine and imaging, Hematology
Published
2022
Full Text
View/download PDF

9. 179: EARLY PREDICTION OF PATHOLOGICAL RESPONSE TO NEOADJUVANT CHEMORADIOTHERAPY FOR OESOPHAGEAL CANCER USING FULLY HYBRID PET/MR: PRELIMINARY RESULTS

Author

D Palumbo, C Fiorino, M Mori, M Picchio, A Cossu, N Slim, F Puccetti, E Mazza, S Steidler, N Di Muzio, S Cascinu, L Gianolli, R Rosati, and F De Cobelli

Subjects
Gastroenterology, General Medicine
Abstract

Background and aim Despite adequate preoperative staging, 25% of patients with oesophageal cancer treated with primary surgery have microscopically positive resection margins (R1), and the 5-year survival rate rarely exceeds 40%. The CROSS trial demonstrated that neoadjuvant chemoradiotherapy (nCRT) double the median overall survival, with 29% of patients achieving a pathological complete response. Many authors suggest that this subgroup of patients do not benefit from additional surgery also having regard to the fact that oesophageal resections are associated with substantial morbidity and postoperative mortality rates of 3–5%. On the other hand 18% of patients who underwent nCRT were found to be non-responders, only suffering from nCRT side effects. Thus, rationale exists for identifying novel biomarkers allowing early, non-invasive prediction of pathological tumour response. Methods Starting from January 2020, all consecutive patients with biopsy proven potentially resectable oesophageal cancer scheduled to receive nCRT (CROSS regimen) were prospectively enrolled. In addition to standard of care imaging, a fully integrated hybrid PET/MR was performed at three time points (prior to, during and six weeks after treatment completion). For each patient, an early regression index (ERI) was computed according to the formula: ERI = ln [1—(tumour volume mid/tumour volume pre) tumour volume pre]. Tumour volumes were contoured on axial high resolution T2 weighted images by an experienced radiologist. Finally, after surgery, these data were systematically correlated with the pathological outcome in terms of Tumour Regression Grade(TRG). TRG = 1 refers to pathological complete response status. Results At present, of ten patients enrolled, seven underwent surgery after completion of nCRT; of these, three patients had TRG = 1. Interestingly, patients with a pathological complete response demonstrated significantly lower ERI values when compared with those patients with TRG ≥ 2 (4.09 vs. 27.94, P Conclusion Preliminary results point out the existence of a novel imaging, MR based biomarker (ERI), able to early predict pathological tumour response during nCRT, thus providing an actual aid for patients’ management. The research leading to these results has received funding from AIRC (Italian Association for Cancer Research) under Investigator Grant—IG 2019—ID. 23015 project; NCT04359732.

Published
2022
Full Text
View/download PDF

11. Development and validation of a novel nomogram predicting long-term progression in patients treated with early salvage radiation therapy after radical prostatectomy: the key role of PSA kinetics

Author

P. Scilipoti, N. Fossati, E. Mazzone, J.R. Karnes, S.A. Boorjian, G. Motterle, A. Bossi, T. Kumar, N. Di Muzio, C. Cozzarini, B. Noris Chiorda, D. Robesti, G. Cirulli, G. Gandaglia, N. Suardi, D. Bartkowiak, S. Shariat, G. Goldner, C. Berghen, S. Joniau, A. Stabile, V. Cucchiara, H. van Poppel, G. De Meerleer, P. Karakiewicz, T. Wiegel, F. Montorsi, and A. Briganti

Subjects
Urology
Published
2022
Full Text
View/download PDF

12. PO-1139 Skin toxicity in 1325 breast cancer patients treated with hypofractionated RT without boost

Author

Chiara Brombin, Chiara Lucrezia Deantoni, Paola Mangili, Lucia Perna, A. Del Vecchio, Pier Giorgio Esposito, A.M. Deli, M.S. Di Serio, N. Di Muzio, Anna Chiara, A. Sanchez Galvan, Sara Broggi, Roberta Castriconi, Italo Dell'Oca, Paola M.V. Rancoita, R. Tummineri, Flavia Zerbetto, M. Pasetti, Andrei Fodor, Claudio Fiorino, and Barbara Longobardi

Subjects
Oncology, medicine.medical_specialty, Breast cancer, Skin toxicity, business.industry, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Hematology, business, medicine.disease
Published
2021
Full Text
View/download PDF

13. PO-1342 Trends and predictors of worsening at RT end of anxiety and depression during RT for prostate cancer

Author

A. Bresolin, Elisabetta Garibaldi, E. Olivetta, Alessandro Magli, A. Faiella, Cristina Piva, P. Ferrari, Fabio Badenchini, Marco Gatti, N. Di Muzio, Giuseppe Sanguineti, Tiziana Rancati, Eugenio Villa, Barbara Avuzzi, Domenico Cante, Fernando Munoz, L. Ferella, Giuseppe Girelli, V. Vavassori, Claudio Fiorino, Cesare Cozzarini, J.M. Waskiewicz, Riccardo Valdagni, E. Moretti, and B. Noris Chiorda

Subjects
Oncology, medicine.medical_specialty, business.industry, Hematology, medicine.disease, Prostate cancer, Internal medicine, medicine, Anxiety, Radiology, Nuclear Medicine and imaging, medicine.symptom, business, Depression (differential diagnoses)
Published
2021
Full Text
View/download PDF

14. PD-0769 Patient-reported acute intestinal toxicity and impact on patient QoL after WPRT for prostate cancer

Author

Giuseppe Girelli, Cristina Piva, L. Ferella, Domenico Cante, Barbara Avuzzi, Riccardo Valdagni, E. Moretti, Alessandro Magli, J.M. Waskiewicz, A. Pastorino, Marco Gatti, A. Bresolin, Claudio Fiorino, N. Di Muzio, Tiziana Rancati, Eugenio Villa, B. Noris Chiorda, Giuseppe Sanguineti, Cesare Cozzarini, B. Farina, A. Faiella, V. Vavassori, Fabio Badenchini, P. Ferrari, and Fernando Munoz

Subjects
Oncology, medicine.medical_specialty, Prostate cancer, business.industry, Intestinal toxicity, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Hematology, business, medicine.disease
Published
2021
Full Text
View/download PDF

15. PH-0660 Independent role of dose-escalation and prophylactic WPRT in salvage RT after radical prostatectomy

Author

B. Noris Chiorda, Chiara Lucrezia Deantoni, A. Briganti, E. Olivetta, Andrei Fodor, Claudio Fiorino, Cristina Piva, Alessandro Magli, N. Fossati, A. Pastorino, Giuseppe Sanguineti, F. Montorsi, G. Gandaglia, Barbara Avuzzi, A. Faiella, Domenico Cante, Riccardo Valdagni, N. Di Muzio, Fernando Munoz, Cesare Cozzarini, S. Marco Andrea, and L. Ferella

Subjects
medicine.medical_specialty, Oncology, Prostatectomy, business.industry, medicine.medical_treatment, medicine, Dose escalation, Urology, Radiology, Nuclear Medicine and imaging, Hematology, business
Published
2021
Full Text
View/download PDF

16. Toxicity of Hypofractionated Whole Breast Radiotherapy Without Boost and Timescale of Late Skin Responses in a Large Cohort of Early-Stage Breast Cancer Patients

Author

Roberta Castriconi, Barbara Longobardi, Pier Giorgio Esposito, Ariadna Sanchez Galvan, Antonella del Vecchio, N. Di Muzio, Mariaclelia Stefania Di Serio, Paola M.V. Rancoita, A.M. Deli, Chiara Brombin, Paola Mangili, Andrei Fodor, Claudio Fiorino, Chiara Lucrezia Deantoni, Marcella Pasetti, Italo Dell'Oca, R. Tummineri, and Flavia Zerbetto

Subjects
Oncology, Cancer Research, medicine.medical_specialty, business.industry, Breast Neoplasms, Middle Aged, medicine.disease, Mastectomy, Segmental, Whole breast radiotherapy, Large cohort, Cohort Studies, Breast cancer, Internal medicine, Toxicity, Medicine, Humans, Female, Radiation Dose Hypofractionation, Radiotherapy, Adjuvant, Stage (cooking), business
Abstract

To report toxicity of hypofractionated whole-breast radiotherapy in a large cohort of early-stage breast cancer (BCaients.From 02/2009-05/2017, 1325 consecutive BCa patients were treated with 40.05 Gy/15 fractions, without boost. Median age was 62 (IQR:51.1-70.5) years. Chemotherapy was prescribed for 28% of patients, hormonal therapy for 80.3%, monoclonal antibodies for 8.2%.Median follow-up was 72.4 (IQR: 44.6-104.1) months. Acute RTOG toxicity was: 69.8% Grade (G) 1, 14.3% G2 and 1.7% G3. Late SOMA-LENT toxicities were: edema-hyperpigmentation (E-H): G1 28.67%, G2 4.41%, G3 0.15%; fibrosis-atrophy-telangiectasia-pain (F-A-T-P): G1 14.6%, G2 3.2%, G3 0.8%, G4 0.1%. Median time to first occurrence was 6 and 18 months, respectively. Aesthetic result after surgery was excellent in 28.7%, good in 41.5%, acceptable in 20.3% and poor in 9.5% of patients. Change in breast appearance after radiotherapy was mild in 6.9%, moderate in 2.3% and marked in 1.3% of patients. Concomitant chemotherapy, obesity, smoking, use of bolus and planning target volume (PTV) were associated with higher acute toxicity. Patients ≥55 years old were less likely to experience acute toxicity. PTV and acute G2 toxicity were associated with ≥G2 E-H. PTV, concomitant chemotherapy, hypertension and ≥G2 acute toxicity were associated with increased risk of F-A-T-P.Hypofractionated whole-breast radiotherapy without boost demonstrated mild acute and late toxicity in a large cohort of consecutive patients. Moderate and marked changes in breast appearance were registered for 3.6% of patients and occurred between 18 to 42 months.

Published
2021

17. PD34-02 THE KEY ROLE OF PSA DOUBLING TIME IN PATIENTS TREATED WITH SALVAGE RADIATION THERAPY AFTER RADICAL PROSTATECTOMY: IMPLICATIONS FOR THE EXTENT OF RADIATION AND THE CONCOMITANT USE OF HORMONAL THERAPY

Author

J.R. Karnes, N. Di Muzio, Detlef Bartkowiak, F. Montorsi, S.F. Shariat, Gregor Goldner, G. Gandaglia, Alberto Bossi, S. Joniau, A. Briganti, G. De Meerleer, Thomas Wiegel, B. Noris Chiorda, H. Van Poppel, Elio Mazzone, Cesare Cozzarini, Charlien Berghen, Stephen A. Boorjian, T. Kumar, N. Fossati, Giovanni Motterle, and Daniele Robesti

Subjects
medicine.medical_specialty, Salvage radiation, business.industry, Prostatectomy, Urology, Concomitant, medicine.medical_treatment, Medicine, Hormonal therapy, Doubling time, In patient, business
Published
2021
Full Text
View/download PDF

18. PD-0414 Trend over time of patient-reported QoL domains after pelvic nodal irradiation for prostate cancer

Author

A. Faiella, A. Gebbia, E. Villa, J.M. Waskiewicz, A. Magli, B. Avuzzi, E. Garibaldi, D. Cante, G. Girelli, M. Gatti, L. Ferella, B. Noris Chiorda, L. Rago, P. Ferrari, A. Bresolin, C. Piva, F. Badenchini, T. Rancati, R. Valdagni, V. Vavassori, F. Munoz, G. Sanguineti, N. Di Muzio, C. Fiorino, and C. Cozzarini

Subjects
Oncology, Radiology, Nuclear Medicine and imaging, Hematology
Published
2022
Full Text
View/download PDF

23. PSA doubling time as predictor of relapse after early salvage radiation therapy: When should imaging be used to select patients who might not benefit from early local treatments?

Author

N. Fossati, J.R. Karnes, S.A. Boorjan, A. Bossi, N. Di Muzio, C. Cozzarini, B. Noris Chiorda, G. Gandaglia, E. Mazzone, A. Stabile, D. Bartkowiak, S. Shariat, G. Goldner, S. Joniau, C. Berghen, G. De Meerleer, H. Van Poppel, A. Gallina, F. Montorsi, T. Wiegel, and A. Briganti

Subjects
Urology
Published
2022
Full Text
View/download PDF

24. Development and validation of a novel nomogram predicting long-term progression in patients treated with early salvage radiation therapy after radical prostatectomy: The key role of PSA kinetics

Author

N. Fossati, E. Mazzone, R.J. Karnes, S.A. Boorjian, G. Motterle, A. Bossi, T. Kumar, N. Di Muzio, C. Cozzarini, B. Noris Chiorda, D. Robesti, A. Stabile, G. Gandaglia, N. Suardi, D. Bartkowiak, S.F. Shariat, G. Goldner, S. Joniau, H. Van Poppel, C. Berghen, G. De Meerleer, P. Karakiewicz, F. Montorsi, T. Wiegel, and A. Briganti

Subjects
Urology
Published
2022
Full Text
View/download PDF

25. A Multicenter Large Retrospective Database on the Personalization of Stereotactic Ablative Radiotherapy for Lung Metastases From Colon-Rectal Cancer: The LaIT-SABR Study

Author

Davide Franceschini, Stefano Maria Magrini, Sara Ramella, Vieri Scotti, F. Casamassima, L. Frassinelli, Frank Lohr, Luigi Corti, N. Di Muzio, Claudia Sangalli, I. Fazio, F. Perrone, M. Perna, Stefano Arcangeli, R.M. Niespolo, D. Aiello, Lorenzo Livi, Francesco Pasqualetti, Marta Scorsetti, M. Franceschini, G. Mortellaro, M.F. Osti, B. De Bari, A. Ravasio, Riccardo Valdagni, M. Sepulcri, Silvia Chiesa, Ernesto Maranzano, V. Valentini, A. Di Marzo, F.M. Aquilanti, Fabiola Paiar, Alessio Bruni, Andrei Fodor, Paolo Borghetti, A. Iurato, Filippo Alongi, Michele Rigo, Marianna Alessandra Gerardi, Giampaolo Montesi, Luca Nicosia, L. Vavassori, Rosario Mazzola, Barbara Alicja Jereczek-Fossa, Nicosia, L, Franceschini, D, Perrone, F, Casamassima, F, Gerardi, M, Perna, M, Scotti, V, Fodor, A, Mazzola, R, Rigo, M, Iurato, A, Pasqualetti, F, Chiesa, S, Niespolo, R, Bruni, A, Frassinelli, L, Borghetti, P, Marzo, A, Ravasio, A, De Bari, B, Sepulcri, M, Aiello, D, Mortellaro, G, Sangalli, C, Franceschini, M, Montesi, G, Aquilanti, F, Valdagni, R, Fazio, I, Corti, L, Vavassori, L, Maranzano, E, Magrini, S, Lohr, F, Arcangeli, S, Valentini, V, Paiar, F, Ramella, S, Di Muzio, N, Livi, L, Jereczek-Fossa, B, Osti, M, Scorsetti, M, and Alongi, F

Subjects
Cancer Research, Univariate analysis, medicine.medical_specialty, Radiation, Predictive marker, Colorectal cancer, business.industry, medicine.medical_treatment, medicine.disease_cause, medicine.disease, SABR volatility model, Primary tumor, Radiation therapy, Lesion, colorectal metastase, Oncology, medicine, Radiology, Nuclear Medicine and imaging, KRAS, Radiology, oligometastase, medicine.symptom, business, SABR
Abstract

PURPOSE/OBJECTIVE(S): stereotactic ablative radiotherapy (SABR) has been shown to increase survival rates in oligometastatic disease (OMD), but local control of colorectal metastases still remains poor. We aimed to identify potential predictive factors of SBRT response through a multicenter large retrospective database and to investigate how lung SBRT can impact on the progression to the polymetastatic disease (PMD). MATERIALS/METHODS: the study involved 22 centers, and was approved by the Ethical Committee (Prot. Negrar 2019-ZT). 1023 lung metastases treated with SBRT in 622 patients were reported. The median BED was 105 Gy10. Lesion diameter GTV, PTV volume, dose, fractionations, and site of primary tumor were evaluated as potential predictive marker for SBRT response for the primary end-point local progression-free survival (LPFS). EGFR, KRAS, NRAS, BRAF, and MSI were also evaluated. Secondary end-point was the time to the polymetastatic conversion (ttPMC). RESULTS: the median follow-up was 26 months (range 3-117 months). The median lesion diameter was 13 mm (range 4-58 mm). The 2- and 3-year LPFS were 75.6% and 71%, respectively. At the univariate analysis, BED ≥125Gy10 was associated with improved LPFS (2-year: 94.1% versus 72.6%; P = < 0.0001), single fraction SBRT correlated with better LPFS in the overall population (2-year: 80.6% versus 73.7%; P = 0.03), but no significant difference was observed when considering the population treated with BED > 100 Gy10. Lesion diameter ≤19 mm correlated with improved LPFS (2-year 80% versus 60%; P = < 0.0001). The median ttPMC was 26 months, and the 2-year ttPMC was 54.5%. The median PFS was 11.3 months. After SABR, 36% patients had polymetastatic relapse, 39.5% patients had an oligometastatic relapse, and 24.5% patients had no further relapse. CONCLUSION: the present is the largest series of lung colorectal metastases treated with SABR. The results support the use of SBRT in lung oligometastatic colorectal cancer patients as it might delay the transition to PMD or offer relatively long disease-free period in selected cases. Several biological and clinical predictive factors were identified to assure the highest local control, on the basis of which a decisional algorithm will be derived.

Published
2021
Full Text
View/download PDF

27. What is the optimal duration of hormonal treatment during salvage radiotherapy in men with pN1 prostate cancer? Results form a large multi-institutional series

Author

S.F. Shariat, B. Noris Chiorda, Gregor Goldner, S. Joniau, H. Van Poppel, Elio Mazzone, Cesare Cozzarini, Charlien Berghen, Stephen A. Boorjian, N. Di Muzio, Vito Cucchiara, Robert Jeffrey Karnes, G. Gandaglia, Giovanni Motterle, T. Kumar, N. Fossati, Armando Stabile, Daniele Robesti, F. Montorsi, G. De Meerleer, A. Briganti, Detlef Bartkowiak, Thomas Wiegel, and Alberto Bossi

Subjects
Oncology, medicine.medical_specialty, Series (stratigraphy), business.industry, Internal medicine, Salvage radiotherapy, PN1 Prostate Cancer, Urology, medicine, Duration (project management), business, Hormone
Published
2021
Full Text
View/download PDF

28. Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized?

Author

Sara Broggi, Andrei Fodor, Claudio Fiorino, Pier Giorgio Esposito, Paolo Passoni, Italo Dell'Oca, R. Tummineri, Flavia Zerbetto, Najla Slim, Paola Mangili, Chiara Brombin, Oreste Gentilini, Marcella Pasetti, Chiara Lucrezia Deantoni, Stefano L. Villa, N. Di Muzio, Fulvio Borroni, Roberta Castriconi, Barbara Longobardi, Giampaolo Bianchini, Paola M.V. Rancoita, S. Baroni, Mariaclelia Stefania Di Serio, A.M. Deli, Anna Chiara, Lucia Perna, Antonella del Vecchio, Fodor, A., Brombin, C., Mangili, P., Borroni, F., Pasetti, M., Tummineri, R., Zerbetto, F., Longobardi, B., Perna, L., Dell'Oca, I., Deantoni, C. L., Deli, A. M., Chiara, A., Broggi, S., Castriconi, R., Esposito, P. G., Slim, N., Passoni, P., Baroni, S., Villa, S. L., Rancoita, P. M. V., Fiorino, C., Del Vecchio, A., Bianchini, G., Gentilini, O. D., Di Serio, C., and Di Muzio, N. G.

Subjects
medicine.medical_specialty, Receptor, ErbB-2, Tumor bed boost, medicine.medical_treatment, Breast cancer conservative treatment, Hypofractionated whole breast radiotherapy, Breast Neoplasms, Mastectomy, Segmental, lcsh:RC254-282, Gastroenterology, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Interquartile range, Median follow-up, Internal medicine, medicine, Carcinoma, Humans, 030212 general & internal medicine, Stage (cooking), skin and connective tissue diseases, Chemotherapy, business.industry, General Medicine, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Radiation therapy, 030220 oncology & carcinogenesis, Early stage breast cancer, Hormonal therapy, Surgery, Female, Radiation Dose Hypofractionation, Original Article, Neoplasm Recurrence, Local, business, Breast cancer molecular subtypes
Abstract

Aim We report molecular subtype impact on 1325 early breast cancer (BCa) patients treated with whole breast hypofractionated (WBH) adjuvant forward-planned intensity modulated radiotherapy (F-IMRT) without boost. Methods and materials From 02/2009-05/2017 1325 patients with pTis-pT3, pNx-N1aM0 BCa who underwent breast conservation surgery were treated with WBHF-IMRT in our institute, to a total dose of 40 Gy/15 fractions, without boost. Median age: 62 (interquartile range-IQR-:51.14–70.53) years. Histology: 8% in situ carcinoma (ISC), 92% invasive tumors. Molecular subtypes (invasive tumors): 49.9% Luminal A, 33.1% Luminal B Her2 negative (−), 6.2% Luminal B Her2 positive (+), 3.6% Hormone Receptor (HR)- Her2+, 7.1% Triple negative (TNBC), and 0.2% HR+. Chemotherapy (CT) was prescribed in 28% of patients, hormonal therapy in 80.3%, monoclonal antibodies (MAb) in 86.8% of Luminal B Her2+ and 97.7% of HR- Her2+ patients. Results Median follow up was 72.43 (IQR: 44.63–104.13) months. The 5-year Kaplan-Meier estimates of local relapse-free survival (LRFS) was 97.8%, regional-(RRFS) 98.6%, loco-regional- (LRRFS) 96.9%, distant- (DRFS) 96.6%, disease-free survival (DFS) 94.8% and overall survival (OS) 95.5%. Considering molecular subtypes, 5-year LRFS was: 99.8% for Luminal A, 96.7% for Luminal B Her2-, 94.1% for Luminal B Her2+, 87.9% for HR- Her2+, 95.1% for TNBC and 99.1% for in situ carcinoma. Conclusion While the overall estimated probability of LR within 5 years after WBHF-IMRT without boost is good (2.2%), molecular subtypes have a strong impact, despite MAb therapy in Her2+ patients, and CT for TNBC patients, and could be used as a parameter in deciding the boost prescription., Highlights • Hypofractionated three-weeks radiotherapy ensures good local control whitout boost. • In 1325 early stage breast cancers 5-year local relapse without boost was 2.2%. • Molecular subtypes have a strong impact on estimated probability of local relapse. • 5-year local control (LC) was 99.8% for Luminal A vs 87.9% for HR- Her2+. • 5-year LC was 96.7% for Luminal B Her2-, 94.1% for Luminal B Her2+, 95.1% for TNBC.

Published
2021

29. Stereotactic ablative radiotherapy in castration-resistant prostate cancer patients with oligoprogression during androgen receptor-targeted therapy

Author

Luca Marinelli, Giulio Francolini, Stefano Maria Magrini, Daniela Musio, Maurizio Valeriani, Alessio Bruni, Beatrice Detti, Ernesto Maranzano, Saverio Caini, Cynthia Aristei, N. Di Muzio, Andrei Fodor, Andrea Lancia, Simona Borghesi, Gianluca Ingrosso, D. Russo, Fabio Trippa, Lorenzo Livi, Luca Triggiani, Ingrosso, G., Detti, B., Fodor, A., Caini, S., Borghesi, S., Triggiani, L., Trippa, F., Russo, D., Bruni, A., Francolini, G., Lancia, A., Marinelli, L., Di Muzio, N., Livi, L., Magrini, S. M., Maranzano, E., Musio, D., Aristei, C., and Valeriani, M.

Subjects
Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Oligoprogression, medicine.drug_class, Stereotactic body radiotherapy, medicine.medical_treatment, Kaplan-Meier Estimate, Radiosurgery, Targeted therapy, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Internal medicine, Androgen Receptor Antagonists, medicine, Humans, Molecular Targeted Therapy, Survival analysis, Androgen receptor-targeted therapy, Aged, Retrospective Studies, Analysis of Variance, business.industry, Metastatic castration-resistant prostate cancer, NEST-free survival, Hazard ratio, Radiotherapy Dosage, Common Terminology Criteria for Adverse Events, General Medicine, Middle Aged, Androgen, medicine.disease, Combined Modality Therapy, Progression-Free Survival, Radiation therapy, Prostatic Neoplasms, Castration-Resistant, Treatment Outcome, 030104 developmental biology, 030220 oncology & carcinogenesis, Toxicity, Disease Progression, business
Abstract

Objectives: To report outcomes of stereotactic body radiotherapy (SBRT) in metastatic castration-resistant prostate cancer (mCRPC) patients with oligoprogression (≤ 5 metastases) during first-line treatment with androgen receptor-targeted therapy (ARTT). Patients and methods: Retrospective multi-institutional analysis of mCRPC patients treated with SBRT to oligoprogressive lesions during ARTT. End-points were time to next-line systemic treatment (NEST), radiological progression-free survival (r-PFS) and overall survival (OS). Toxicity was registered according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Survival analysis was performed using the Kaplan–Meier method, univariate and multivariate analysis (MVA) were performed. Results: Data from 34 patients were analyzed. Median NEST-free survival, r-PFS, and OS were 16.97, 13.47, and 38.3months, respectively. At MVA, factors associated with worse NEST-free survival and r-PFS were polymetastatic burden at diagnosis of metastatic hormone-sensitive disease (hazard ratio [HR] 3.66, p = 0.009; HR 3.03, p = 0.034), PSA ≤ 7ng/ml at mCRPC diagnosis (HR 0.23, p = 0.017; HR 0.19, p = 0.006) and PSADT ≤ 3months at mCRPC diagnosis (HR 3.39, p = 0.026; HR 2.79, p = 0.037). Polymetastatic state at mHSPC diagnosis was associated with a decreased OS (HR 4.68, p = 0.029). No patient developed acute or late grade ≥ 2 toxicity. Conclusion: Our results suggest that SBRT in oligoprogressive mCPRC is safe, effective and seems to prolong the efficacy of the ongoing systemic treatment positively affecting disease progression. Prospective trials are needed.

Published
2021

30. Assessing the impact of salvage radiation therapy field after radical prostatectomy: a long-term analysis from a large multi-institutional series

Author

S. Joniau, Stephen A. Boorjian, H. Van Poppel, N. Di Muzio, Daniele Robesti, S.F. Shariat, Alberto Bossi, G. De Meerleer, Robert Jeffrey Karnes, Thomas Wiegel, Detlef Bartkowiak, Francesco Barletta, A. Briganti, Gregor Goldner, Elio Mazzone, Charlien Berghen, Giovanni Motterle, F. Montorsi, Simone Scuderi, Gaëtan Devos, B. Noris Chiorda, G. Gandaglia, Cesare Cozzarini, T. Kumar, and N. Fossati

Subjects
medicine.medical_specialty, Series (stratigraphy), Field (physics), Prostatectomy, business.industry, medicine.medical_treatment, Urology, lcsh:Diseases of the genitourinary system. Urology, lcsh:RC870-923, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, Term (time), Salvage radiation, medicine, Radiology, business
Published
2020

31. Assessing the optimal timing of salvage radiation therapy administration after radical prostatectomy: A stage-specific analysis from a large multi-institutional series

Author

Elio Mazzone, Charlien Berghen, S.A. Boorjan, Thomas Wiegel, S.F. Shariat, Gaëtan Devos, A. Briganti, G. De Meerleer, Cesare Cozzarini, Daniele Robesti, G. Gandaglia, Detlef Bartkowiak, Alberto Bossi, J.R. Karnes, H. Van Poppel, Aldo Rizzo, Giovanni Motterle, Donato Cannoletta, N. Di Muzio, Francesco Barletta, S. Joniau, F. Montorsi, T. Kumar, N. Fossati, Gregor Goldner, and B. Noris Chiorda

Subjects
medicine.medical_specialty, Series (stratigraphy), business.industry, Prostatectomy, medicine.medical_treatment, Urology, lcsh:Diseases of the genitourinary system. Urology, lcsh:RC870-923, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, Surgery, Salvage radiation, medicine, Stage specific, business, Administration (government)
Published
2020

32. Comprehensive Intra-Institution stepping validation of knowledge-based models for automatic plan optimization

Author

Riccardo Calandrino, Cesare Cozzarini, Sara Broggi, Claudio Fiorino, Giovanni Mauro Cattaneo, Roberta Castriconi, N. Di Muzio, Castriconi, R., Fiorino, C., Broggi, S., Cozzarini, C., Di Muzio, N., Calandrino, R., and Cattaneo, G. M.

Subjects
medicine.medical_specialty, Computer science, Radiotherapy Planning, Computer-Assisted, Biophysics, General Physics and Astronomy, General Medicine, Plan (drawing), Models, Theoretical, Equivalent uniform dose, Prostate radiotherapy, 030218 nuclear medicine & medical imaging, Automation, 03 medical and health sciences, 0302 clinical medicine, Penile bulb, 030220 oncology & carcinogenesis, Machine learning, medicine, Radiology, Nuclear Medicine and imaging, Medical physics, Automatic planning, Knowledge-based
Abstract

Purpose To develop and apply a stepping approach for the validation of Knowledge-based (KB) models for planning optimization: the method was applied to the case of concomitant irradiation of pelvic nodes and prostate + seminal−vesicles bed irradiation in post-prostatectomy patients. Methods The clinical VMAT plans of 52 patients optimized by two reference planners were selected to generate a KB-model (RapidPlan, v.13.5 Varian). A stepping-validation approach was followed by comparing KB-generated plans (with and without planner-interaction, RP and only-RP respectively) against delivered clinical plans (RA). The validation followed three steps, gradually extending its generalization: 20 patients used to develop the model (closed-loop); 20 new patients, same planners (open-loop); 20 new patients, different planners (wide-loop). All plans were compared, in terms of relevant dose-volume parameters and generalized equivalent uniform dose (gEUD). Results KB-plans were generally better than or equivalent to clinical plans. For RPvsRA, PTVs coverage was comparable, for OARs RP was always better. Comparing only-RPvsRA, PTVs coverage was always better; bowel\bladder V50Gy and D1%, bowel\bladder\rectum Dmean, femoral heads V40Gy and penile bulb V50Gy were significantly improved. For RPvsRA gEUD reduction >1 Gy was seen in 80% of plans for rectum, bladder and bowel; for only-RPvsRA, this was found in 50% for rectum/bladder and in 70% for bowel. Conclusion An extensive stepping validation approach of KB-model for planning optimization showed better or equal performances of automatically generated KB-plan compared to clinical plans. The interaction of a planner further improved planning performances.

Published
2019
Full Text
View/download PDF

34. FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients

Author

Maria Picchio, Sara Broggi, M. Pasetti, A.M. Samanes Gajate, Andrei Fodor, Claudio Fiorino, Elena Incerti, Italo Dell'Oca, L. Gianolli, M. Cuzzocrea, Paola Mapelli, M. Cattaneo, Riccardo Calandrino, N. Di Muzio, Incerti, E., Broggi, S., Fodor, A., Cuzzocrea, M., Samanes Gajate, A. M., Mapelli, P., Fiorino, C., Dell’Oca, I., Pasetti, M., Cattaneo, M., Calandrino, R., Gianolli, L., Di Muzio, N., and Picchio, Maria

Subjects
Adult, Male, Mesothelioma, Radiology, Nuclear Medicine and Imaging, Poor prognosis, Lung Neoplasms, MTV, TLG, Survival, medicine.medical_treatment, Malignant pleural mesothelioma, Logistic regression, Disease-Free Survival, Tomotherapy, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, Helical tomotherapy, Fluorodeoxyglucose F18, Predictive Value of Tests, Positron Emission Tomography Computed Tomography, medicine, Humans, Radiology, Nuclear Medicine and imaging, Aged, Aged, 80 and over, Chemotherapy, Proportional hazards model, business.industry, Pleural mesothelioma, Mesothelioma, Malignant, General Medicine, Middle Aged, FDG PET/CT, Total lesion glycolysis, 030220 oncology & carcinogenesis, Female, Radiopharmaceuticals, business, Nuclear medicine, Median survival
Abstract

Purpose: The value of FDG PET-derived parameters in predicting overall survival (OS), local relapse-free survival (LRFS) and distant relapse-free survival (DRFS) in treated patients with malignant pleural mesothelioma (MPM) was evaluated. Methods: This retrospective evaluation included 55 MPM patients treated between March 2006 and February 2015 with FDG PET/CT-guided salvage helical tomotherapy (HTT) after previous surgery plus chemotherapy. Univariate Cox regression analysis was performed to assess the impact of the following FDG PET-derived parameters: biological target volume (BTV), mean and maximum standardized uptake values (SUVmean/max), metabolic tumour volume (MTV) and total lesion glycolysis (TLG), measured using different uptake thresholds (40%, 50% and 60%). Logistic regression was then performed to identify the best FDG PET-derived parameters for selecting patients with poorer survival. Results: The median OS was 9.1months (range 0.0 – 69.6months) after the end of HTT; 54/55 patients were dead at the last follow-up. BTV and TLG40, TLG50 and TLG60 were the most significant predictors of OS (p< 0.005). The median OS was 4.8months in patients with MTV60 >5cm3 and TLG40 >334.4, compared with 13.8months and 16.1months in patients with smaller values, respectively. The median LRFS and DRFS were 6.2months (range 1.2 – 39.4months) and 6.5months (0.0 – 66.4months), respectively. TLG40, TLG50 and TLG60 were significantly correlated with LRFS (p< 0.015). Median DRFS was 6.4months in patients with MTV40 >39.6cm3 and 6.2months in patients with TLG40 >334.4, compared with 17months and 18.8months in patients with smaller values. BTV, TLG40 and MTV40 were also found to be good predictors in patients with poor OS/LRFS/DRFS (median survival times less than the median values). Conclusion: FDG PET-derived parameters effectively discriminated patients with a poor prognosis and may be helpful in the selection of MPM patients for salvage HTT.

Published
2018
Full Text
View/download PDF

35. Which patients should be still considered for late salvage radiotherapy for rising or persistently elevated PSA after radical prostatectomy: Results from a large multi-institutional study

Author

B. Noris Chiorda, N. Fossati, J. Karnes, M. Soligo, S. Boorjian, A. Bossi, G. Coraggio, N. Di Muzio, C. Cozzarini, C. Fiorino, G. Gandaglia, D. Robesti, D. Bartkowiak, V. Budach, S. Shariat, G. Goldner, A. Battaglia, S. Joniau, K. Haustermans, G. De Meerleer, V. Fonteyne, P. Ost, H. Van Poppel, F. Montorsi, T. Wiegel, and A. Briganti

Subjects
medicine.medical_specialty, business.industry, Prostatectomy, Urology, Salvage radiotherapy, medicine.medical_treatment, Medicine, business, Elevated PSA
Published
2018
Full Text
View/download PDF

36. PO-1345 Symptoms affecting Emotional, Systemic and Social Domains 2 years after RT for prostate cancer

Author

Eugenio Villa, A. Pastorino, Cristina Piva, J.M. Waskiewicz, Riccardo Valdagni, Giuseppe Sanguineti, Giuseppe Girelli, A. Bresolin, B. Noris Chiorda, V. Vavassori, L. Ferella, Alessandro Magli, Domenico Cante, Tiziana Rancati, P. Ferrari, Elisabetta Garibaldi, E. Olivetta, A. Faiella, N. Di Muzio, Barbara Avuzzi, Claudio Fiorino, Angelo Maggio, Cesare Cozzarini, Fabio Badenchini, Fernando Munoz, and Marco Gatti

Subjects
Oncology, medicine.medical_specialty, Prostate cancer, business.industry, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Hematology, medicine.disease, business
Published
2021
Full Text
View/download PDF

37. PO-1354 Time Dependence of PSADT prognostic threshold in men treated with post-prostatectomy salvage RT

Author

E. Olivetta, Cristina Piva, L. Andreoli, A. Faiella, B. Noris Chiorda, A. Pastorino, Riccardo Valdagni, F. Montorsi, N. Di Muzio, Cesare Cozzarini, F. Tonetto, Giuseppe Sanguineti, Flavia Zerbetto, Andrei Fodor, Claudio Fiorino, N. Fossati, Barbara Avuzzi, Chiara Lucrezia Deantoni, Domenico Cante, A. Briganti, G. Gandaglia, and Alessandro Magli

Subjects
medicine.medical_specialty, Oncology, business.industry, Urology, Medicine, Radiology, Nuclear Medicine and imaging, Hematology, business, Post prostatectomy
Published
2021
Full Text
View/download PDF

38. PO-1025 Outcomes of re-irradiation of relapsed intracranic lesions with stereotactic radiotherapy

Author

N. Di Muzio, Sergio Villa, Andrei Fodor, A.M. Deli, Sara Broggi, A. Sanchez Galvan, Flavia Zerbetto, S. Baroni, A. Del Vecchio, G. Mandurino, R. Tummineri, P. Pacifico, and Chiara Lucrezia Deantoni

Subjects
Re-Irradiation, Stereotactic radiotherapy, Oncology, business.industry, Medicine, Radiology, Nuclear Medicine and imaging, Hematology, business, Nuclear medicine
Published
2021
Full Text
View/download PDF

39. PO-1214 Toxicity profile of adjuvant hypofractionated Image-Guided Radiotherapy in biliary tract carcinoma

Author

Najla Slim, P. Pacifico, A.M. Deli, Stefano Cascinu, F. De Cobelli, L. Aldrighetti, Paolo Passoni, N. Di Muzio, A. Casadei Gardini, Monica Ronzoni, R. Tummineri, Claudio Fiorino, and F. Pedica

Subjects
medicine.medical_specialty, Oncology, business.industry, medicine.medical_treatment, medicine, Radiology, Nuclear Medicine and imaging, Hematology, Radiology, Image guided radiotherapy, business, Biliary tract carcinoma, Adjuvant, Toxicity profile
Published
2021
Full Text
View/download PDF

40. PO-1225 Hypofractionated radiotherapy after induction chemotherapy for advanced pancreatic cancer

Author

Gianpaolo Balzano, A. Del Vecchio, Renato Castoldi, Michele Reni, Stefano Cascinu, Giulia Orsi, N. Di Muzio, Massimo Falconi, Najla Slim, M. Macchini, Barbara Longobardi, Sara Broggi, U. Peretti, M. Mori, Paolo Passoni, Claudio Fiorino, and Giovanni Mauro Cattaneo

Subjects
Oncology, Hypofractionated Radiotherapy, medicine.medical_specialty, business.industry, Pancreatic cancer, Internal medicine, Medicine, Induction chemotherapy, Radiology, Nuclear Medicine and imaging, Hematology, business, medicine.disease
Published
2021
Full Text
View/download PDF

41. PO-1307 Extended nodal radiotherapy for relapsed gynecologic tumors with PET/CT-guided SIB

Author

Flavia Zerbetto, Chiara Lucrezia Deantoni, Paola Mangili, S. Baroni, Sergio Villa, A. Del Vecchio, A. Sanchez Galvan, G. Mandurina, R. Tummineri, N. Di Muzio, Stefano Arcangeli, P. Pacifico, and Andrei Fodor

Subjects
Radiation therapy, PET-CT, Oncology, business.industry, medicine.medical_treatment, medicine, Radiology, Nuclear Medicine and imaging, Hematology, NODAL, business, Nuclear medicine
Published
2021
Full Text
View/download PDF

42. PH-0112 Multicenter large retrospectIve database on SBRT for colorectal lung metastases: the LaIT-SABR study

Author

Riccardo Valdagni, L. Vavassori, Michele Rigo, Marianna Alessandra Gerardi, B. De Bari, N. Di Muzio, Barbara Alicja Jereczek-Fossa, Vieri Scotti, Frank Lohr, M. Perna, Filippo Alongi, Luigi Corti, I. Fazio, R.M. Niespolo, G. Mortellaro, F.M. Aquilanti, Andrei Fodor, Paolo Borghetti, M.F. Osti, Luca Nicosia, A. Ravasio, Davide Franceschini, L. Frassinelli, A. Di Marzo, G. Gadducci, A. Iurato, Fabiola Paiar, D. Aiello, Alessio Bruni, F. Casamassima, Sara Ramella, Silvia Chiesa, Rosario Mazzola, F. Perrone Congedi, Stefano Arcangeli, Stefano Maria Magrini, M. Franceschini, Lorenzo Livi, M. Sepulcri, Francesco Pasqualetti, Claudia Sangalli, Marta Scorsetti, Ernesto Maranzano, Giampaolo Montesi, and V. Valentini

Subjects
medicine.medical_specialty, Lung, medicine.anatomical_structure, Oncology, business.industry, Medicine, Radiology, Nuclear Medicine and imaging, Hematology, Radiology, business, SABR volatility model, Retrospective database
Published
2021
Full Text
View/download PDF

43. PO-1401 Lung metastasis from renal cell carcinoma: SBRT alone or in association with target therapy as a potential treatment option

Author

Flavia Zerbetto, Chiara Lucrezia Deantoni, T. Roberta, Sara Broggi, N. Di Muzio, M. Pasetti, S. Foti, and Anna Chiara

Subjects
Oncology, medicine.medical_specialty, business.industry, Lung metastasis, Treatment options, Hematology, medicine.disease, Renal cell carcinoma, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, Target therapy, business
Published
2021
Full Text
View/download PDF

44. PD-0767 Predictors of urinary incontinence 2 years after RT with different intents for prostate cancer

Author

Fabio Badenchini, J.M. Waskiewicz, Eugenio Villa, Riccardo Valdagni, Alessandro Magli, E. Moretti, Domenico Cante, Fernando Munoz, P. Ferrari, B. Noris Chiorda, A. Faiella, Elisabetta Garibaldi, Giuseppe Sanguineti, N. Di Muzio, Cristina Piva, Cesare Cozzarini, L. Ferella, V. Vavassori, Marco Gatti, Giuseppe Girelli, Claudio Fiorino, Barbara Avuzzi, Tiziana Rancati, and A. Bresolin

Subjects
medicine.medical_specialty, Prostate cancer, Oncology, business.industry, Urology, Medicine, Radiology, Nuclear Medicine and imaging, Urinary incontinence, Hematology, medicine.symptom, business, medicine.disease
Published
2021
Full Text
View/download PDF

45. PO-1563 A dose-escalation for early-regression based ART for rectal cancer: a planning feasibility study

Author

Najla Slim, Sara Broggi, Paola Mangili, Claudio Fiorino, A. Del Vecchio, Paolo Passoni, A. Cicchetti, and N. Di Muzio

Subjects
Oncology, medicine.medical_specialty, Colorectal cancer, business.industry, Internal medicine, medicine, Dose escalation, Radiology, Nuclear Medicine and imaging, Hematology, medicine.disease, business, Regression
Published
2021
Full Text
View/download PDF

46. PO-1131 Primary tumors observed in 1325 consecutive breast cancer patients treated with whole breast RT

Author

Chiara Lucrezia Deantoni, Flavia Zerbetto, A.M. Deli, M.S. Di Serio, Andrei Fodor, Claudio Fiorino, Sara Broggi, Paola Mangili, Barbara Longobardi, A. Del Vecchio, Italo Dell'Oca, Roberta Castriconi, Pier Giorgio Esposito, R. Tummineri, N. Di Muzio, Chiara Brombin, and M. Pasetti

Subjects
Oncology, medicine.medical_specialty, Breast cancer, business.industry, Internal medicine, Medicine, Radiology, Nuclear Medicine and imaging, Hematology, Whole breast, business, medicine.disease
Published
2021
Full Text
View/download PDF

47. PD-0747 Knowledge-based approach for DVH prediction in robotic spine SBRT

Author

N. Di Muzio, Chiara Lucrezia Deantoni, Paola Mangili, Alessia Tudda, Sara Broggi, A. Del Vecchio, Lucia Perna, Andrei Fodor, Claudio Fiorino, Roberta Castriconi, and Barbara Longobardi

Subjects
Spine (zoology), medicine.medical_specialty, Oncology, business.industry, medicine, Radiology, Nuclear Medicine and imaging, Hematology, Radiology, business
Published
2021
Full Text
View/download PDF

48. PD-0910 Radical radiotherapy in lymph node or bone metastatic prostate cancer: a single institution series

Author

Roberta Castriconi, Andrei Fodor, Claudio Fiorino, N. Di Muzio, S. Baroni, Sergio Villa, G. Mandurino, Chiara Lucrezia Deantoni, A. Sanchez Galvan, Cesare Cozzarini, R. Tummineri, and P. Pacifico

Subjects
Series (stratigraphy), medicine.medical_specialty, business.industry, Radical radiotherapy, Hematology, medicine.disease, Prostate cancer, medicine.anatomical_structure, Oncology, Medicine, Radiology, Nuclear Medicine and imaging, Radiology, Single institution, business, Lymph node
Published
2021
Full Text
View/download PDF

49. PD-0782 Predicting bRFS after salvage post-prostatectomy RT with a 'one-size-fits-all' TCP-based formula

Author

B. Noris Chiorda, Fernando Munoz, Alessandro Magli, A. Pastorino, Barbara Avuzzi, E. Olivetta, Marco Signor, Giuseppe Sanguineti, Riccardo Valdagni, N. Di Muzio, M. Olivieri, Chiara Lucrezia Deantoni, Andrei Fodor, Claudio Fiorino, Domenico Cante, Sara Broggi, A. Faiella, Tiziana Rancati, L. Ferella, Cesare Cozzarini, and Cristina Piva

Subjects
medicine.medical_specialty, Oncology, business.industry, Urology, medicine, Radiology, Nuclear Medicine and imaging, Hematology, business, Post prostatectomy
Published
2021
Full Text
View/download PDF

50. PO-1212 Outcome of adjuvant hypofractionated radiotherapy concomitant to chemotherapy in bile duct carcinoma

Author

L. Aldrighetti, N. Di Muzio, Monica Ronzoni, A. Casadei Gardini, F. Pedica, F. De Cobelli, P. Pacifico, Paolo Passoni, Claudio Fiorino, Stefano Cascinu, A.M. Deli, Najla Slim, and R. Tummineri

Subjects
Hypofractionated Radiotherapy, medicine.medical_specialty, Chemotherapy, business.industry, medicine.medical_treatment, Urology, Hematology, Bile Duct Carcinoma, Oncology, Concomitant, Medicine, Radiology, Nuclear Medicine and imaging, business, Adjuvant
Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results